Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2009

View Archived Issues

Boehringer Ingelheim claims new oncolytic PI3K inhibitors in recent patent

New PAI-1 inhibitors claimed by Kowa for treating thrombotic disorders

Novel cannabinoid CB1 receptor antagonists discovered at Schering-Plough

Novo Nordisk reviews Q4 progress

iTherX to initiate proof-of-concept study for ITX-5061 in hepatitis C

Prasugrel receives approval recommendation from FDA Advisory Committee

Pfizer's Sutent is recommended as first-line treatment for kidney cancer

Allos reports results from pivotal pralatrexate trial in peripheral T-cell lymphoma

GSK and Theravance announce positive results from three fluticasone furoate trials

OncoGenex provides 2-year survival data from ongoing OGX-011 trial

Abraxis BioScience launches Abraxane in Germany

JMR-132, AN-162 demonstrate ovarian tumor growth inhibition in xenograft models

Alseres completes enrollment in Altropane POET-2 phase III program

Medivir selects MIV-710 as a candidate drug for osteoporosis and osteoarthritis

Novel T-type calcium channel inhibitors discovered by Merck & Co. researchers

Novel TNF-alpha production inhibitors reported by Daiichi Sankyo for treatment of sepsis

CyDex successfully completes phase II clinical trial of Captisol-Enabled nasal spray in SAR

Isoform-selective phospholipase D inhibitors developed at Vanderbilt University

Waiting period expires for MAP and AstraZeneca's agreement for budesonide

Warner Chilcott acquires NexMed's alprostadil for erectile dysfunction

Human ProIslet Peptide stimulates islet neogenesis

FDA approves Galderma's Vectical for mild to moderate plaque psoriasis

Peregrine announces results from phase II clinical trial of bavituximab in NSCLC

European Commission clears acquisition of Zentiva by sanofi-aventis

FDA Advisory Committee favors approval of DX-88 for hereditary angioedema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...